New natural treatment for common colds
Announcement posted by Mundipharma 17 May 2018
Mundipharma launches mundicare® Cold Defence nasal spray
When taken at the first signs of a cold, mundicare® Cold Defence Nasal Spray is clinically proven to:
Mundipharma has introduced a new early treatment to help families stay healthy and fight against the common cold.
Common colds are viral infections that typically affect adults two to four times per year and children as often as five to 10 times each year.10 The burden of a cold can be even more pronounced in the elderly, children and those with existing illnesses or risk factors.
Clinical trials including more than 350 adults and children have shown that mundicare® Cold Defence Nasal Spray reduced the duration of colds by up to two days and reduced severity of symptoms in children and adults1-3. It also led to up to 99% reduction in the amount of virus found in the nasal lining after 3-5 days1-3.
The treatment contains the natural ingredient iota-carrageenan, also called Carragelose™, derived from red seaweed. It is available in adult and children’s formulations and is recommended for use at the first sign of symptoms.
Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is an exciting development in the fight against the common cold.”
Jane Orr, Managing Director of Mundipharma Australia and New Zealand, said “Every year the common cold puts pressure on families, drains productivity and sick leave, and interferes with daily life,” Ms Orr said. “As an early treatment to manage colds, mundicare® Cold Defence Nasal Spray can help keep families and workplaces healthy and productive.”
Most existing common cold treatments only target symptoms rather than underlying infections, and many over the counter cough and cold medicines are restricted to children over six years old.
mundicare® Cold Defence is preservative, steroid and medicine free.
mundicare® Cold Defence can be purchased from leading pharmacies across Australia and retails for $14.95.
Always read the label. Use only as directed. If symptoms persist, see your healthcare professional.
About Mundipharma
Mundipharma is a member of a global network of independent associated companies, which
are engaged in research, development, production and marketing of prescription medicines
and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include a range of effective products in across pain, oncology, ophthalmology, respiratory, hydration, first aid and common cold.
For more information please visit: www.mundipharma.com.au.
For media inquiries please contact:
Rob Bates
Mb. 0422 196 238
Email Rob.Bates@mundipharma.com.au
For product information please contact:
Joern Packross
Mb. 0457 700 467
Email Joern.Packross@mundipharma.com.au
References: 1. Ludwig M et al. Efficacy of a carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respiratory Research 2013;14:124. 2. Koenighofer M et al.
Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014;9:57. 3. Fazekas
T et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common
cold. BMC Complementary and Alternative Medicine 2012;12:147. 4. Eccles R et al. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebocontrolled
exploratory study in volunteers with early symptoms of the common cold. Respiratory Research 2010;11:108. 5. Eccles R et al. Efficacy and safety of iota-carrageenan nasal spray
versus placebo in early treatment of the common cold in adults: the ICICC trial. Respiratory Research 2015; 16:121. 6. MUNDICARE® COLD DEFENCE KIDS Nasal Spray Leaflet. 7. MUNDICARE® COLD DEFENCE Nasal Spray Leaflet 8. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Amanda R McCullough, Allan J Pollack, Malene Plejdrup Hansen, Paul P Glasziou, David FM Looke, Helena C Britt and Christopher B Del Mar. Medical Journal of Australia. 2017; 207 (2): 65-69. 9. Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2016: first Australian report on antimicrobial use and resistance in human health – consumer summary. Sydney: ACSQHC, 2016. 10. Healthdirect Australia
®MUNDICARE is a registered trade mark.
™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417.®MUNDICARE is a registered trade mark.
™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417.
AU-4507 – 16042018
-ENDS-
- Shorten the duration of a cold by up to 2 days1-3
- Reduce up to 99 per cent of cold viruses from the nasal lining within 3-5 days1-3
- Prevent colds by forming a protective barrier in the nasal lining to trap common cold viruses, helping the body’s natural defences eliminate them
- Reduce the severity of common cold symptoms4-5
- Is preservative, steroid and medicine free
- Can be used during pregnancy and breastfeeding7
- GPs prescribe antibiotics at a rate up to nine times higher than the current guidelines recommend8
- In a recent study more than 50 per cent of people with colds and upper respiratory tract infections were prescribed antibiotics, despite having no benefit in infections caused by viruses9
- Over prescription of antibiotics can contribute to antimicrobial resistance.9
Mundipharma has introduced a new early treatment to help families stay healthy and fight against the common cold.
Common colds are viral infections that typically affect adults two to four times per year and children as often as five to 10 times each year.10 The burden of a cold can be even more pronounced in the elderly, children and those with existing illnesses or risk factors.
Clinical trials including more than 350 adults and children have shown that mundicare® Cold Defence Nasal Spray reduced the duration of colds by up to two days and reduced severity of symptoms in children and adults1-3. It also led to up to 99% reduction in the amount of virus found in the nasal lining after 3-5 days1-3.
The treatment contains the natural ingredient iota-carrageenan, also called Carragelose™, derived from red seaweed. It is available in adult and children’s formulations and is recommended for use at the first sign of symptoms.
Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is an exciting development in the fight against the common cold.”
Jane Orr, Managing Director of Mundipharma Australia and New Zealand, said “Every year the common cold puts pressure on families, drains productivity and sick leave, and interferes with daily life,” Ms Orr said. “As an early treatment to manage colds, mundicare® Cold Defence Nasal Spray can help keep families and workplaces healthy and productive.”
Most existing common cold treatments only target symptoms rather than underlying infections, and many over the counter cough and cold medicines are restricted to children over six years old.
mundicare® Cold Defence is preservative, steroid and medicine free.
mundicare® Cold Defence can be purchased from leading pharmacies across Australia and retails for $14.95.
Always read the label. Use only as directed. If symptoms persist, see your healthcare professional.
About Mundipharma
Mundipharma is a member of a global network of independent associated companies, which
are engaged in research, development, production and marketing of prescription medicines
and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include a range of effective products in across pain, oncology, ophthalmology, respiratory, hydration, first aid and common cold.
For more information please visit: www.mundipharma.com.au.
For media inquiries please contact:
Rob Bates
Mb. 0422 196 238
Email Rob.Bates@mundipharma.com.au
For product information please contact:
Joern Packross
Mb. 0457 700 467
Email Joern.Packross@mundipharma.com.au
References: 1. Ludwig M et al. Efficacy of a carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respiratory Research 2013;14:124. 2. Koenighofer M et al.
Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014;9:57. 3. Fazekas
T et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common
cold. BMC Complementary and Alternative Medicine 2012;12:147. 4. Eccles R et al. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebocontrolled
exploratory study in volunteers with early symptoms of the common cold. Respiratory Research 2010;11:108. 5. Eccles R et al. Efficacy and safety of iota-carrageenan nasal spray
versus placebo in early treatment of the common cold in adults: the ICICC trial. Respiratory Research 2015; 16:121. 6. MUNDICARE® COLD DEFENCE KIDS Nasal Spray Leaflet. 7. MUNDICARE® COLD DEFENCE Nasal Spray Leaflet 8. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Amanda R McCullough, Allan J Pollack, Malene Plejdrup Hansen, Paul P Glasziou, David FM Looke, Helena C Britt and Christopher B Del Mar. Medical Journal of Australia. 2017; 207 (2): 65-69. 9. Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2016: first Australian report on antimicrobial use and resistance in human health – consumer summary. Sydney: ACSQHC, 2016. 10. Healthdirect Australia
®MUNDICARE is a registered trade mark.
™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417.®MUNDICARE is a registered trade mark.
™ CARRAGELOSE is a trade mark of Marinomed Biotech AG used under license. RM-BET-1773-V1-0417.
AU-4507 – 16042018
-ENDS-